Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Darinaparsin - Solasia Pharma

Drug Profile

Darinaparsin - Solasia Pharma

Alternative Names: Darvias; SP-02; SP-02L; Zinapar; ZIO-101

Latest Information Update: 18 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Texas A&M University; University of Texas M. D. Anderson Cancer Center
  • Developer Nippon Kayaku; Solasia Pharma; ZIOPHARM Oncology
  • Class Amines; Antineoplastics; Arsenicals; Oligopeptides; Pentanoic acids; Small molecules; Sulfides
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Discontinued Liver cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 17 Jul 2023 Solasia Pharma announces intention to file for regulatory approval for Peripheral T-cell lymphoma in South America (Solasia Pharma pipeline, July 2023)
  • 24 Aug 2022 Solasia plans a phase II/III trial in Peripheral T-cell lymphoma in European Union (Solasia Pharma pipeline, August 2022)
  • 22 Aug 2022 First global launch - Launched for Peripheral T-cell lymphoma (Second-line therapy or greater) in Japan (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top